Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04792645 · ClinicalTrials.gov registry record · Phase 2
Memantine in Body Focused Repetitive Behaviors
A Phase 2 study of Trichotillomania (Hair-Pulling Disorder) and Dermatillomania, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04792645 is a Phase 2 study of Trichotillomania (Hair-Pulling Disorder) and Dermatillomania that has completed, run by University of Chicago. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04792645, a Phase 2 study of Trichotillomania (Hair-Pulling Disorder) and Dermatillomania, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is 8 weeks long and involves subjects taking memantine or placebo. If they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either memantine or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Memantine
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2022-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04792645
The ClinicalTrials.gov registry entry for NCT04792645 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Trichotillomania (Hair-Pulling Disorder) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04792645 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04792645 about?
NCT04792645 is a clinical study titled "Memantine in Body Focused Repetitive Behaviors". This study is 8 weeks long and involves subjects taking memantine or placebo. If they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. Efficacy and saf...
What is the current status of trial NCT04792645?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2021-06-15. Estimated completion is 2022-07-08.
What conditions does trial NCT04792645 study?
This clinical trial studies the following conditions: Trichotillomania (Hair-Pulling Disorder), Dermatillomania.
What interventions are being tested in trial NCT04792645?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT04792645?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04792645 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trichotillomania (Hair-Pulling Disorder)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.